No traveler was found to have had a greater than or equal to fourfold increase in serology post-treatment. It is postulated that travelers are more likely to demonstrate a fourfold decrease in serology due to a shorter duration of infection and a lower parasite burden which results in a lower antigen load and therefore a more rapid serological decline. The

possible explanations for why this change was not seen in immigrants include failed treatment, reexposure, or serology performed too early to demonstrate a decline. Nevertheless, in our study it is believed that FDA approved Drug Library all patients received effective schistosomiasis treatment with praziquantel and eradicated their infection based on the known effectiveness of the drug, our relatively high dosing regime, and no

documented cases with evidence of persisting infection (symptoms, parasite detection on microscopy, or eosinophilia). Furthermore, investigators also enquired into reexposure risk and patients who were possibly reinfected were excluded from the study. The results of this study are comparable to a previous study by Whitty et al.2 which observed variable ELISA antibody titer response within the first 3 to 5 months after treatment, with an increase in 22%, decrease in 46%, and unchanged in 32%. However, this was not a prospective long-term follow-up study and did not differentiate between travelers and immigrants. Using the immunofluorescence antibody test (IFAT), Tarp et selleck products al. also observed variable serological change within the first 10 months post-treatment.10 The finding of increasing antibody titers performed in the early months post-treatment supports our findings,

and it appears that the different serological methods used do not affect this trend. In three reported returned travelers to Italy where longer term follow-up serology was performed, two patients achieved Casein kinase 1 a fourfold decrease in serology 6 to 18 months post-treatment.14 A limitation of our study was that a proportion of the patients only had a single documented post-treatment serology and those with multiple follow-up serologies often had these performed at variable times. This likely reflects the itinerant characteristics of returned travelers and immigrants who have often presented through asymptomatic screening. It may also be a result of selection bias, whereby those with abnormal results are more likely to return for follow-up. In conclusion, we have described the natural history of schistosomiasis serology in travelers and immigrants who have been adequately treated with praziquantel, showing that titers can increase in the first 6 to 12 months post-treatment, especially in immigrants. For most travelers, the titers will fall significantly with time; however, even up to 3 years’ post-treatment only two thirds achieve a fourfold decrease.